Global Neural Implants Market 2025-2035

Description

List of Tables

Neural Implants Market Size, Share & Trends Analysis Report by Product (Deep Brain Stimulation (DCS), Spinal Cord Stimulation (SCS), and Vagus Nerve Stimulation (VNS)), by Application (Chronic Pain, Epilepsy, Parkinson's Disease (PD), and Others (Depression and Other Movement Disorders)), and by End-User (Hospitals, Outpatient Surgery Centers, and Specialized Neurological Centers (SNCs)), Forecast Period (2025-2035)

Industry Overview

Neural implants market was valued at $7.9 billion in 2024 and is projected to reach $26.8 billion by 2035, growing at a CAGR of 11.8% during the forecast period (2025-2035). The neural implants market is witnessing steady expansion owing to advances in neuromodulation technologies and increasing clinical applications across neurological disorders. Growing investment in research is leading to more precise, less invasive, and patient-specific implant designs. The rising burden of conditions such as epilepsy and treatment-resistant depression is further fueling demand for innovative solutions. Hospitals and specialized centers are increasingly adopting implants as part of comprehensive treatment programs. Supportive regulatory approvals and wider reimbursement coverage are encouraging adoption.

Market Dynamics

Rising Adoption of Neural Implants for Chronic Pain Management

The growing prevalence of chronic pain disorders has accelerated demand for spinal cord stimulation (SCS) implants. These devices help patients reduce opioid dependence and improve quality of life through targeted neuromodulation. Advancements in miniaturization and rechargeable systems are making implants more patient-friendly. Companies are actively expanding portfolios with next-generation SCS systems. For instance, Boston Scientific Corp. offers the WaveWriter Alpha SCS system, enabling personalized therapy. This trend is expected to significantly support market growth over the coming years.

Increasing Use of Deep Brain Stimulation in Parkinson's Disease Treatment

Deep brain stimulation (DBS) has grown into a cornerstone therapy for patients with Parkinson's disease who no longer respond adequately to medications. The technology enhances motor control and reduces tremors through precise electrical impulses. Growing clinical evidence and regulatory approvals are strengthening adoption rates globally. Moreover, innovation in adaptive and MRI-compatible devices is improving safety and outcomes. For instance, Medtronic plc provides Percept PC with BrainSense technology, offering continuous brain activity data. This growing preference for DBS implants highlights a major expansion driver for the global neural implants market.

Market Segmentation

Based on the product, the market is segmented into deep brain stimulation (DCS), spinal cord stimulation (SCS), and vagus nerve stimulation (VNS).
Based on the application, the market is segmented into chronic pain, epilepsy, parkinson's disease (PD), and others (depression and other movement disorders.
Based on the end-user, the market is segmented into hospitals, outpatient surgery centers, and specialized neurological centers (SNCs).

Deep Brain Stimulation (DBS) Segment to Lead the Market with the Largest Share

The demand for deep brain stimulation systems is increasing as patients seek long-term management options for complex neurological conditions. DBS has shown effectiveness in improving motor function and reducing symptoms that are resistant to conventional therapies. Continuous innovation is making these implants safer and more adaptable to individual needs. For instance, Abbott Laboratories provides the Infinity DBS system, which allows physicians to adjust therapy through a wireless interface. Such solutions are transforming care delivery in neurological disorders. This progress is driving steady momentum in the neural implants market.

Parkinson's Disease (PD): A Key Segment in Market Growth

The growing prevalence of Parkinson's disease is creating a higher demand for neural implants as patients and clinicians look for more effective treatment options. These devices are helping to manage motor symptoms and improve overall quality of life, where medications alone may not be sufficient. Advances in implant design are making therapies more adaptable and easier to monitor. Healthcare providers are increasingly including these solutions as part of long-term treatment strategies. For Instance, Medtronic plc offers the Percept PC neurostimulator with sensing technology designed to optimize therapy for Parkinson's patients. Such innovations are contributing to the steady expansion of the neural implants market.

Regional Outlook

The global neural implants market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Growing Investment in Advanced Healthcare Technologies in Asia-Pacific

The Asia-Pacific neural implant market is expanding owing to the increasing prevalence of neurological disorders, rising investment in advanced healthcare technologies, and growing adoption of minimally invasive neurosurgical procedures. Companies such as Medtronic are introducing innovative implantable devices to address conditions such as Parkinson's disease, epilepsy, and spinal cord injuries. Additionally, supportive government initiatives and rising awareness about brain health are driving demand across the region. The expansion of healthcare infrastructure in emerging economies further fuels market growth. Advances in neurostimulation and biosensing technologies are also enhancing the effectiveness of neural implants.

North America Region Dominates the Market with a Major Share

In North America, advanced healthcare infrastructure and high awareness levels are supporting faster adoption of neural implants. Physicians are increasingly recommending these solutions for conditions where conventional treatment shows limited effectiveness. The region benefits from supportive clinical research and favorable regulatory pathways. Companies are introducing advanced devices that align with patient safety requirements. For instance, NeuroPace, Inc., has developed the RNS System for responsive neurostimulation in epilepsy care. This strong ecosystem is ensuring continued market growth in the region.

Market Players Outlook

The major companies operating in the global neural implants market include Abbott Laboratories, Boston Scientific Corp., LivaNova PLC, Medtronic plc, NEVRO Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In May 2025, Neuralink received Breakthrough Device Designation from the FDA to help restore communication for individuals with severe speech impairment. This includes those affected by ALS, stroke, spinal cord injury, cerebral palsy, multiple sclerosis, and other neurological conditions.
In November 2022, Blackrock Neurotech announced that it had introduced its Neuralace next-generation neural interface for brain-computer interface (BCI) technology. It designed the Neuralace platform as an ultra-high channel count, flexible electrode. The company provides a glimpse into the technology set to fuel its future BCIs.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global neural implants market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023487

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Neural Implants Market Sales Analysis - Product| Application| End-User |($ Million)
Neural Implants Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Neural Implants Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Neural Implants Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Neural Implants Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Neural Implants Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Neural Implants Market Revenue and Share by Manufacturers
Neural Implants Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Boston Scientific Corp.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. LivaNova PLC
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Medtronic plc
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. NEVRO Corp.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Neural Implants Market Sales Analysis by Product ($ Million)

5.1. Deep Brain Stimulation (DCS)
5.2. Spinal Cord Stimulation (SCS)
5.3. Vagus Nerve Stimulation (VNS)

6. Global Neural Implants Market Sales Analysis by Application ($ Million)

6.1. Chronic Pain
6.2. Epilepsy
6.3. Parkinson's Disease (PD)
6.4. Others (Depression and Other Movement Disorders)

7. Global Neural Implants Market Sales Analysis by End-User ($ Million)

7.1. Hospitals
7.2. Outpatient Surgery Centers
7.3. Specialized Neurological Centers (SNCs)

8. Regional Analysis

8.1. North American Neural Implants Market Sales Analysis - Product| Application| End-User | ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Neural Implants Market Sales Analysis - Product| Application| End-User|($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Neural Implants Market Sales Analysis - Product| Application| End-User|($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Neural Implants Market Sales Analysis - Product| Application| End-User|($ Million)
Macroeconomic Factors for Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Abbott Laboratories
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Alejandro Neuroelectronics, Inc.
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. Aleva Neurotherapeutics SA
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. BioControl Medical Ltd.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. BlueWind Medical Ltd.
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. Boston Scientific Corp.
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Functional Neuromodulation Ltd.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Inspire Medical Systems, Inc.
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. LivaNova PLC
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. Mainstay Medical International plc
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. Medtronic plc
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. NeuroEM Therapeutics, Inc.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Neuronetics, Inc.
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. NeuroPace, Inc.
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. NeuroSigma, Inc.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. NEVRO Corp.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Nuvectra Corp.
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Saluda Medical Pty Ltd.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Soterix Medical Inc.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Synapse Biomedical Inc.
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies